Chemotherapy News and Research

Latest Chemotherapy News and Research

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

New insight into treatment patterns for people with stage two and three rectal cancer

Research from the University of Alberta provides new insight into treatment patterns for people with stage two and three rectal cancer-information that ultimately will help physicians improve care strategies for patients provincewide.

16 May 2012

Better understanding of new T-size descriptors on adjuvant chemotherapy effect needed

The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer.

16 May 2012

CINJ prefers more personalized approach to prescribing cancer treatment

With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over "one-size-fits-all" methods.

16 May 2012

VATS plays a valuable role in lung cancer screening program

The most recent research released in June's Journal of Thoracic Oncology says video assisted thoracic surgery (VATS) is a valuable tool in managing lesions detected in a lung cancer screening program.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

15 May 2012

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd., for the joint discovery and development of new Affilin therapeutics to treat various diseases.

15 May 2012

Latest statistics: Cancer deaths in 50-59 year olds have dropped to 14,000

The number of people in their 50s dying prematurely from cancer in the UK has fallen below 14,000 for the first time in 40 years according to new Cancer Research UK figures published today.

15 May 2012

Analysis stresses importance of multidisciplinary approach to cancer in the elderly

New research showing that almost half of 13,000 patients with head and neck cancers had other health-related problems at the same time is one of the presentations in a special session at the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) today.

14 May 2012

New combination therapy offers potential lifetime cure for advanced type 1 diabetes

City of Hope researchers developed a combination therapy to treat late-stage type 1 diabetes that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study is published in the May 9 edition of Science Translational Medicine.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

$EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL$

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it has received conditional marketing authorization from the European Commission for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

11 May 2012

IGABT effective at controlling return and spread of cervical cancer

Delivering radiotherapy directly to cancer of the cervix using 3-D imaging techniques is effective at controlling the return and spread of the disease and, in most cases, avoids the need for hysterectomies, according to research presented at the World Congress of Brachytherapy today.

11 May 2012

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."

11 May 2012

Fast track approval process for “breakthrough” drugs proposed in the U.S.

Some experimental drugs that show a big effect early in development for treating serious or life-threatening diseases could soon get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year.

10 May 2012

Researchers develop potent new drug that can kill tumor cells

All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.

9 May 2012

IBN develops biochip for investigating the effect of drugs on cancer stem cells

Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs). Published recently in Nano Today, this new technology could boost the development of more effective cancer drugs.

9 May 2012

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two patients have been enrolled into REALISTIC, a Phase 1/2 study being sponsored by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

8 May 2012

Can curry really be beneficial for cancer?

Curcumin is found in the spice turmeric has been linked to a range of health benefits. Studies have already shown that it can beat cancer cells grown in a laboratory and benefits have been suggested in stroke and dementia patients as well. Cucurmin, which acts as an antioxidant and has anti-inflammatory properties, has traditionally been used as an alternative remedy for liver disease, digestive disorders, acne and a range of allergies. Some studies have shown it may slow the spread of cancer, boost the effectiveness of chemotherapy and protect healthy cells from the effects of radiotherapy.

8 May 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

New insight into treatment patterns for people with stage two and three rectal cancer

Better understanding of new T-size descriptors on adjuvant chemotherapy effect needed

CINJ prefers more personalized approach to prescribing cancer treatment

VATS plays a valuable role in lung cancer screening program

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Latest statistics: Cancer deaths in 50-59 year olds have dropped to 14,000

Analysis stresses importance of multidisciplinary approach to cancer in the elderly

New combination therapy offers potential lifetime cure for advanced type 1 diabetes

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

IGABT effective at controlling return and spread of cervical cancer

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Fast track approval process for “breakthrough” drugs proposed in the U.S.

Researchers develop potent new drug that can kill tumor cells

IBN develops biochip for investigating the effect of drugs on cancer stem cells

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

Can curry really be beneficial for cancer?

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Newsletters you may be interested in